USFDA inspects Aurobindo Pharma’s Formulation manufacturing facility in Telangana

22 Jul 2023 Evaluate

The United States Food and Drug Administration (USFDA) has inspected Aurobindo Pharma’s Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana, from July 14, 2023 to July 21, 2023.

At the end of the inspection, the company has been issued a ‘Form 483’ with 3 observations. The observations are procedural in nature. It will respond to the USFDA within the stipulated timelines and work closely with US FDA to close the observations at the earliest. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1121.65 -18.65 (-1.64%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×